Riskpilot← Back to searchSign inGet full accessAbboxia AB
ABActiveOrg 5569249187Johannefredsgatan 4Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20137 employees
Revenue 2024
SEK 48M
-28% vs 2024
EBITDA margin
24.6%
-20% vs 2024
Equity ratio
47.6%
Financial strength
Net profit 2024
SEK 6,3M
-19% vs 2024
| Revenue | SEK 48M | -28% |
| EBITDA | SEK 11,8M | -20% |
| Net profit | SEK 6,3M | -19% |
| Total assets | SEK 41,2M | -10% |
| Equity | SEK 19,6M | -6% |
| Employees | 7 | — |
Legal name
Abboxia AB
Org number
5569249187
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
5 mars 2013
Share capital
SEK 50 000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att bedriva försäljning av läkemedel, läkemedelsnära produkter och annan därmed förenlig verksamhet. Vidare ska bolaget bedriva konsultverksamhet inom ovan nämnda områden, bedriva handel med värdepapper samt därmed förenlig verksamhet. Bolaget ska dessutom förvalta fast egendom samt därmed förenlig verksamhet.
Address
Johannefredsgatan 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 3 882 | 7 789 | 13 368 | 19 394 | 36 997 | 66 292 | 47 999 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 2 | −24 | −1 037 | 1 420 | 1 361 | 2 712 | 5 508 | 11 734 | 14 757 | 11 811 |
| Depreciation & amort. | −0 | −0 | −0 | −114 | −188 | −184 | −286 | −589 | −1 136 | −1 374 |
| EBIT | 2 | −24 | −1 037 | 1 306 | 1 173 | 2 528 | 5 222 | 11 145 | 13 621 | 10 437 |
| Net financials | — | — | −11 | −33 | −37 | −47 | −80 | −319 | −100 | 8 |
| Profit before tax | 2 | −24 | −1 049 | 1 273 | 554 | 2 617 | 3 751 | 10 607 | 9 826 | 8 167 |
| Tax | −0 | −0 | −0 | −98 | −131 | −568 | −779 | −2 206 | −2 046 | −1 861 |
| Net profit | 2 | −24 | −1 049 | 1 175 | 423 | 2 049 | 2 972 | 8 401 | 7 780 | 6 306 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 50 | 626 | 788 | 3 760 | 5 746 | 9 461 | 19 298 | 31 226 | 45 736 | 41 245 |
| Equity | 50 | 626 | 77 | 1 252 | 1 675 | 3 724 | 6 695 | 12 996 | 20 777 | 19 622 |
| Long-term debt | 0 | 0 | 511 | 1 545 | 2 080 | 2 125 | 4 914 | 6 324 | 0 | 0 |
| Short-term debt | 0 | 0 | 199 | 963 | 1 409 | 3 166 | 5 851 | 9 849 | 19 210 | 13 594 |
| Total debt | — | — | 710 | 2 508 | 3 489 | 5 291 | 10 765 | 16 173 | 19 210 | 13 594 |
EBITDA margin
24.6%
This company
15.8%
Market median
+56% vs market
20162024
Equity ratio
47.6%
This company
38.2%
Market median
+25% vs market
20162024
Return on equity
32.1%
This company
18.4%
Market median
+74% vs market
20162024
Net profit margin
13.1%
This company
8.1%
Market median
+62% vs market
20162024
Asset turnover
1.16×
This company
1.12×
Market median
+4% vs market
20162024
Debt / equity
1.10×
This company
0.62×
Market median
-77% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-05-01 – 2024-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-05-01 – 2020-04-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-05-01 – 2019-04-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-05-01 – 2016-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LM Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
LT Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
DA | Audit | 2022 | — | — |
CF Chief Executive Officer | Chief Executive Officer | 2026 | — | — |
KK Chief Auditor | Chief Auditor | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Deputy Board Member | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
FrostPharma AB | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Priveq Investment VI (A) AB
Abboxia AB Board members of Abboxia AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Magnus Nylén | Chief Executive Officer | 0 companies |
| Lars Thorbjörn Andreas Skogsberg | Chief Executive Officer | 0 companies |
| Dan Andreas Johansson | Audit | 0 companies |
| Carl Fredrik Oskar S Andersch | Chief Executive Officer | 0 companies |
| Kajsa Karin Helena Goding | Chief Auditor | 0 companies |
| Åsa Elisabeth Israelsson Skogsberg | Deputy Board Member | 0 companies |
| Malin Susanne Tapper | Deputy Board Member | 0 companies |
| Roger Carl-Gunnar Tapper | Chairman | 0 companies |
| Malin Maria Hollander | Deputy Board Member | 0 companies |